Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 185-189

  Alotaibi, Ghazi S ^a   Almodaimegh, Hind ^b   McMurtry, M Sean ^a   Wu, Cynthia ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Bleeding; Novel oral anticoagulants; Sex related differences; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; XIMELAGATRAN;

ARTICLE; BLEEDING; HUMAN; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

BLEEDING; NOVEL ORAL ANTICOAGULANTS; SEX-RELATED DIFFERENCES; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84883817807     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.07.017     Document Type: Article

References (32)

1. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, and G. Palareti Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 2012 e44S e88S
2. M. Zareh, A. Davis, and S. Henderson Reversal of warfarin-induced hemorrhage in the emergency department West J Emerg Med 12 2011 386 392
3. G. Palareti, and B. Cosmi Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients Thromb Haemost 102 2009 268 278
4. A.C. Mauer, N.A. Khazanov, N. Levenkova, S. Tian, E.M. Barbour, and C. Khalida Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults J Thromb Haemost 9 2011 100 108
5. P.M. Kuijer, B.A. Hutten, M.H. Prins, and H.R. Büller Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch Intern Med 159 1999 457 460
6. M. Moscucci, K.A. Fox, C.P. Cannon, W. Klein, J. López- Sendón, and G. Montalescot Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1815 1823
7. C.I. The, "Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative Circulation 114 2006 1380 1387
8. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
9. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
10. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, and D. Baanstra Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
11. G.W. Albers Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials Am J Manag Care 10 2004 S462 S469
12. S. Schulman, K. Wåhlander, T. Lundström, S.B. Clason, and H. Eriksson Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran N Engl J Med 349 2003 1713 1721
13. J.N. Fiessinger, M.V. Huisman, B.L. Davidson, H. Bounameaux, C.W. Francis, and H. Eriksson Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JAMA 293 2005 681 689
14. H. Eriksson, K. Wåhlander, D. Gustafsson, L.T. Welin, L. Frison, and S. Schulman A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I J Thromb Haemost 1 2003 41 47
15. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
16. I. Einstein, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, and H. Decousus Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
17. I. Einstein-Pe, H.R. Büller, M.H. Prins, A.W. Lensin, H. Decousus, and B.F. Jacobson Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
18. G. Agnelli, A. Gallus, S.Z. Goldhaber, S. Haas, M.V. Huisman, and R.D. Hull Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study Circulation 116 2007 180 187
19. H.R. Buller, A.W. Lensing, M.H. Prins, G. Agnelli, A. Cohen, and A.S. Gallus A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study Blood 112 2008 2242 2247
20. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
21. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
22. I. Botticelli, C. Writing, H. Buller, D. Deitchman, M. Prins, and A. Segers Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study J Thromb Haemost 6 2008 1313 1318
23. S.S. Adam, J.R. McDuffie, T.L. Ortel, and J.W. Williams Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Ann Intern Med 157 2012 796 807
24. D. Canadian Agency for and H. Technologies Requirements for health technology assessment template for reports. Ottawa (ON) 2008 The Agency
25. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, and J.P. Ioannidis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ (Clin Res Ed) 339 2009 10
26. G.A. Wells, B. Shea, D. O'connell, J. Peterson, V. Welch, and M. Losos The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 3rd Symposium on Systematic Reviews: Beyond the Basics 2000 3 5
27. P.L. Santaguida, and P. Raina The Development of the McHarm Quality Assessment Scale for adverse events: Delphi Consensus on important criteria for evaluating harms. 2008 2008
28. J.P.T. Higgins, D.G. Altman, P.C. Gøtzsche, P. Jüni, D. Moher, and A.D. Oxman The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011
29. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
30. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ (Clin Res Ed) 327 2003 557 560
31. H. Eriksson, T. Lundström, K. Wåhlander, S.B. Clason, and S. Schulman Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran Thromb Haemost 94 2005 522 527
32. S.D. Fihn, M. McDonell, D. Martin, J. Henikoff, D. Vermes, and D. Kent Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Ann Intern Med 118 1993 511 520